Skip to main content
. 2020 Jun 10;37(7):3404–3416. doi: 10.1007/s12325-020-01395-x

Fig. 2.

Fig. 2

Time to first on-study SRE for Asian subgroup. CI confidence interval, HR hazard ratio, N number of patients randomized in Asian subgroup, Q4W every 4 weeks, SRE skeletal-related event. HR < 1 favors denosumab